Nanion Corporate Blog

 

12.04.2019: Assessing cardiotoxic risk of anti-cancer agents on Nanion's CardioExcyte 96

Learn how new anti-cancer agents have led to higher life expectancy for cancer surviving patients, why cardiotoxic side effects such as arrhythmia, thromboembolism and myocardial ischemia are common with anti-cancer drugs such as the anthracyclines and to what degree can advances in human stem cell derived cardiomyocytes (hiPSC-CMs) and patient-derived hiPSC-CMs offer new possibilities for personalized medicine. Read the Application Note here.


Additionally, don’t miss out on Nanion Technologies Newsbites by Signing Up for free here.

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok